Teva Introduces Budeprion XL® [Bupropion Hydrochloride Extended-Release Tablets USP (XL)], 150 mg
North Wales, Pennsylvania, May 30, 2008— Teva Pharmaceuticals is pleased to announce the introduction and availability of Budeprion XL® [Bupropion Hydrochloride Extended-Release Tablets USP (XL)], 150 mg. This product is AB rated and bioequivalent to Wellbutrin XL®* Tablets. With the addition of this new […]

The FDA has approved the following products:

GlaxoSmithKline’s Entereg:
Entereg (alvimopan) is a peripherally-acting mu opioid receptor (PAM-OR) antagonist designed to block the adverse side effects of opioid analgesics on the GI tract without blocking their beneficial analgesic effects.

Tentative approval for Teva’s Lansoprazole, the generic equivalent of Prevacid.
Tentative approval for both Cobalt Labs and Ivax’s Topiramate, […]

Live CEU Program
Alzheimer’s, Memory, and Dementia
Presented by S. Thomas Deahl II, DMD PHD
Wednesday, July 9th 2008
8:30am to 3:30pm
Fetzer Center at WMU
Free parking, bring you own lunch or eat nearby.
Register by credit card by calling 1-800-937-6878
For more information call or email William Urfer 269-381-2256 william@swmpa.org

3rd Annual Preceptor Development Conference
Ferris State University
College of Pharmacy
June 12, 2008
Grand Rapids Medical Education and Research Center
1000 Monroe Avenue
Grand Rapids, MI
5.0 credit hours (0.5 CEU)
There is no fee for this program.
Dear Colleagues,
With the advent of the Accreditation Council for Pharmacy Education (ACPE) Standards 2007, all Colleges of Pharmacy must adopt changes to their experiential programs, […]

SWMPA Dinner / Lecture
Thursday May 22 2008
6:30PM - Refreshments
7:00PM - Dinner and Lecture
Topic:
“Cardiovascular Updates”
Speaker:
Sandra Chase, Pharm D.
Location:
Bravo restaurantacross from the Kalamazoo-Battle Creek International Airport
View Larger Map
2 CEUs Pending
RSVP to william@swmpa.org or call William at (269)381-2256.

Kindly RSVP by May 19, 2008
Graciously sponsored by Diana Cottrell of Forest Pharmaceuticals.

Friday, May 23, is the compliance date for inclusion of the prescriber’s national prescriber identifier (NPI) with provider claim transactions, including prescription and durable medical equipment and supplies. The Centers for Medicare & Medicaid Services has recently added a NPI-related FAQ that clarifies actions to take when the prescriber’s NPI number is missing. more

The FDA has approved the following drugs in April and May:

Taclonex Scalp Suspension (calcipotriene; betamethasone diproprionate) details
A variety of cetirizine products from various vendors continues to enter the marketplace.
Patanase nasal spray (olapatadine) detail
Treximet (sumatriptan/naproxen sodium) detail
Aplenzin (buproprion hydrobromide) detail